INTUITIVE SURGICAL Q1 FY25 earnings call ISRG

The rollout of da Vinci 5 is progressing as expected, with 147 systems placed and over 32,000 procedures performed across various specialties in Q1. The first fully integrated system, featuring software for integrated hub and simulator, was installed in April. Additional features like real-time surgical video review and visual force feedback gauges are pending 510(k) clearance later this year. Broad launch, including meeting customer demand for trade-ins and dual consoles, is anticipated midyear, with regulatory clearances in Japan and Europe expected near the end of 2025.

Force Feedback is a core feature of da Vinci 5, with early single-institution studies showing promising results. One study indicated a significantly higher rate of bowel function recovery (83% vs 25%) in kidney surgery using force feedback instruments. Another preclinical study with novice surgeons demonstrated improved performance by significantly reducing tissue trauma and errors during suturing. While supply for force sensing instruments is currently limited, broad availability is expected near the end of 2025, and more studies are anticipated to publish in 2025 and beyond to validate its impact at scale.

Ion procedures grew 58% to approximately 31,000 in Q1, with the platform receiving clearance in Australia and its first provincial charge code in China. The company is focused on utilization growth in the U.S. and international expansion, estimating U.S. lung biopsy penetration is approaching the halfway point. SP procedure growth accelerated to 94%, driven by strong performance in Korea and early adoption in Europe and Japan. U.S. 510(k) clearance for the da Vinci SP SureForm 45 stapler will support use in thoracic and colorectal indications, with commercialization efforts being measured.

Intuitive Surgical expects tariffs to result in an additional cost of sales of approximately 1.7% of revenue for FY25, leading to a revised gross margin outlook. This impact is roughly split between U.S.-China trade (50%) and imports into the U.S. from other OUS suppliers (40%). The company's strategy involves first assuring supply, then optimizing production costs and rebalancing product flows within its existing manufacturing footprint, and finally assessing adjustments to pricing and supply chain strategy once the trade environment stabilizes. No significant beneficial impact from mitigation measures is expected in 2025.

The company is expanding its manufacturing and R&D footprint significantly. In Q1, two new facilities were opened at its Sunnyvale, California headquarters, totaling over 1.2 million square feet, for da Vinci systems and Ion manufacturing and R&D. These facilities, along with a recently opened factory in Peachtree Corners, Georgia, provide space for midterm growth. New manufacturing facilities are also expected to open in Germany and Bulgaria, and instrument manufacturing capacity will expand in Mexico, aiming for supply availability, quality, and cost advantages from scale and automation.

OUS procedure growth was strong at 24%, driven by India, Korea, distributor markets, and the U.K., where resource consumption savings and addressing waiting lists are key drivers. However, OUS system placements were slightly down, reflecting financial pressures and healthcare spending constraints in key markets like Japan, Germany, and the U.K. The environment in China continues to be challenging due to domestic competition and policy-driven pricing pressure. Management is focused on helping customers increase utilization of existing capacity and expanding leasing options in these markets.